Phathom: 3 Key Takeaways for Long-Term Investors
Back-to-back quarters of operating profit show the company is converting revenue growth into cash, a milestone that matters for debt covenants and financial sustainability.
Phathom reported $84.7 million in net revenues for Q3 2026, marking a 71% year-over-year growth. The company is expanding coverage for VOQUEZNA, its GERD treatment, through initiatives such as educating physicians on prior authorization and offering $0 copay through partner pharmacy BlinkRx. Phathom's second consecutive quarter of operating profitability and positive cash flow demonstrates sustainable growth, with revenue expected to outpace operating expenses, satisfying debt covenants and positioning the company well for the fourth quarter and beyond.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.